Dope Entrepreneurs
  • Research
  • News
  • Articles
  • Reviews
No Result
View All Result
  • Research
  • News
  • Articles
  • Reviews
No Result
View All Result
Dope Entrepreneurs
No Result
View All Result
Home Research

Vedolizumab Shows Promise At Improving Fistulizing Crohn’s Disease

Drug shows promise for fistula response in crohn's disease.

hplictawa@gmail.com' by Editorial Team
May 7, 2022
in Research
0
Vedolizumab Shows Promise At Improving Fistulizing Crohn's Disease
2.8k
SHARES
6.3k
VIEWS
Share on FacebookShare on TwitterShare On Whatsapp

Medically reviewed by Onikepe Adegbola, MD, PhD

Crohn's disease

Crohn’s disease is an inflammatory bowel disease (IBD). It is the most difficult sickness to cure so far. In 10% of individuals, perianal fistulization is the initial symptom of Crohn’s disease.

ADVERTISEMENT

For individuals with fistulizing CD, the ENTERPRISE trial assessed two vedolizumab intravenous dose regimens. Vedolizumab is a monoclonal antibody shown to be a safe and effective Crohn’s disease therapy. It also works to treat ulcerative colitis.

In patients with perianal fistulizing CD, intravenous (IV) doses of vedolizumab 300 mg enhanced fistulae response and perianal disease activity at week 30 according to research published in Clinical Gastroenterology and Hepatology.

ENTERPRISE is a global phase 4 research that looked at two different vedolizumab IV dose regimens for individuals with fistulizing CD. They had 1 to 3 perianal draining fistulas that had been present for 2 weeks before enrollment, and they had been diagnosed with moderate to severe CD 3 months before enrollment.

How did they design this study?

At weeks 0, 2, 6, 14, and 22, researchers gave 300 mg of intravenous vedolizumab to participants at random (the VDZ regimen). At week 10, they added a second dosage (the VDZ+wk10 regimen).

Those with moderate to severe CD with 1–3 active perianal fistulas were given 300 mg vedolizumab intravenously at weeks 0, 2, 6, 14, and 22 (VDZ) or the same regimen plus an extra dose at week 10 (VDZ + wk10).

Effects of Intravenous Vedolizumab

Vedolizumab was used to treat more than half of the patients with fistulizing CD in this research. They reported a 50% reduction in the number of draining perianal fistulae on clinical examination. Although the dose regimes were different, clinically significant decreases in draining fistulas were seen as early as week 2 and lasted until week 30.

However, there was one flaw in this research. Due to the lack of a placebo or seton plus antibiotic arm, the incidence of fistulae closure without vedolizumab therapy could not be assessed.

However, individuals with fistulizing CD who were given vedolizumab maintenance medication had a greater likelihood of closing their fistulas by 52 weeks than those who were given the placebo.

Limitations of the Study

Because of the small number of patients in each group and the likelihood of outliers, there were no conclusive responses about the effect of vedolizumab concentration on fistulae closure in this research. However, they did find that both IV vedolizumab regimens resulted in a persistent improvement in fistulae response from weeks 2 to 30.

Key Takeaway

Both vedolizumab IV 300 mg regimens showed improved fistula response and decreased perianal disease activity. An extra IV dosage of vedolizumab was not shown to enhance outcomes any more than the normal dose at week 10. Because the current therapy for CD is so difficult, more studies on intravenous vedolizumab might lead to better treatment.

The small research population resulting from the early enrollment closure restricts the generalizability of the findings of this study. As a result, more research with bigger sample sizes is required.

 

Reference:

David A.Schwartz, Lauren. Biroule, Karen Lasch, Shashi Adsul, Silvio Danese (2021). Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn’s Disease. Journal of Clinical Gastroenterology and Hepatology, 20(5), 1059-1067 https://doi.org/10.1016/j.cgh.2021.09.028

Tags: CDCrohn's DiseaseIV
hplictawa@gmail.com'

Editorial Team

Related Posts

Clinical Research Suggests Adding a Probiotic to the Diet for Those Dealing With Depression
Research

Clinical Research Suggests Adding a Probiotic to the Diet for Those Dealing With Depression

January 10, 2023
Clinical Research Data Indicates Gut Flora May Be Improved by the Antioxidant Characteristics of Beer Polyphenols
Research

Clinical Research Data Indicates Gut Flora May Be Improved by the Antioxidant Characteristics of Beer Polyphenols

January 10, 2023
FODMAP-Lowering Diet for IBS Patients
Research

FODMAP-Lowering Diet for IBS Patients

December 8, 2022
Next Post
Lifestyle, Environmental, And Behavioral Management Of Inflammatory Bowel Disease

The Benefits Of Probiotics: Study Compares The Effectiveness Of Two Different Strains

Inulin, Choline, Silymarin: Is This The Cure For IBS – C?

Inulin, Choline, Silymarin: Is This The Cure For IBS - C?

Mediterranean Diet vs Low FODMAP Diet_ Which Is Better For IBS_

Mediterranean Diet vs Low FODMAP Diet: Which Is Better For IBS?

Follow Us

  • 9.9k Followers

Recommended

Study Confirms a Direct Relationship of Gut Microbiota with the Brain

Study Confirms A Direct Relationship Of Gut Microbiota With The Brain

10 months ago
Brief Comparison of Effective IBS Treatments

Brief Comparison of Effective IBS Treatments

10 months ago
Gut Virome Can Treat Intestinal And Immunological Diseases

Gut Virome Can Treat Intestinal And Immunological Diseases

10 months ago
Dietary Choices Are Influenced By Gut Microbiota

Dietary Choices Are Influenced By Gut Microbiota

10 months ago

Categories

  • Articles
  • General
  • News
  • Research
  • Reviews

Topics

acid reflux antibiotics bloating capsaicin causes colonoscopy constipation Crohn's Disease deficiency diabetes diarrhea Digestive enzymes diverticulitis fatigue FODMAP gluten-free gut gut bacteria gut health gut microbiome gut microbiota health healthy diet IBD IBS IBS-C IBS diet inflammation inflammatory bowel disease irritable bowel syndrome lactobacillus low FODMAP diet microbiome microbiota peppermint oil probiotic probiotics quality of life research SIBO sucrose intolerance supplement tea therapy treatment
No Result
View All Result
https://casadesante.com https://casadesante.com https://casadesante.com

Highlights

Science-Based Benefits Of Taking Digestive Enzymes For Efficient Digestive Healing

Association of Poor Vitamin and Mineral Intake to Irritable Bowel Syndrome Symptoms

A Systematic Review of the Linkage Between Irritable Bowel Syndrome and Macronutrients

Invitation To Colonoscopy Reduced Incidences Of Cancer But Not Death Through A Gold-Standard Trial

Symptoms, Causes, and Solutions to Vitamin B Deficiencies

A Meta-Analysis: The Diagnostic Yield Of Colonoscopy In IBS Patients For Organic Diseases

Trending

Clinical Research Suggests Adding a Probiotic to the Diet for Those Dealing With Depression
Research

Clinical Research Suggests Adding a Probiotic to the Diet for Those Dealing With Depression

by Ivy Totanes
January 10, 2023
0

A recently published scientific report from Basel, Switzerland, has demonstrated that probiotics can supplement antidepressant treatment. The...

Clinical Research Data Indicates Gut Flora May Be Improved by the Antioxidant Characteristics of Beer Polyphenols

Clinical Research Data Indicates Gut Flora May Be Improved by the Antioxidant Characteristics of Beer Polyphenols

January 10, 2023
FODMAP-Lowering Diet for IBS Patients

FODMAP-Lowering Diet for IBS Patients

December 8, 2022
Science-Based Benefits Of Taking Digestive Enzymes For Efficient Digestive Healing

Science-Based Benefits Of Taking Digestive Enzymes For Efficient Digestive Healing

October 25, 2022
Association of Poor Vitamin and Mineral Intake to Irritable Bowel Syndrome Symptoms

Association of Poor Vitamin and Mineral Intake to Irritable Bowel Syndrome Symptoms

October 18, 2022
Dope Entrepreneurs

Dope Entrepreneurs is the hub for all dope gut health related content. We are a groundbreaking news publication dedicated to gut health. We cover gut health research, entrepreneurship, startups and the latest trends in gut health. We serve a growing segment of patients, entrepreneurs and investors who want to learn more about gut health, the disruption and market potential in this field, and how they can benefit from the latest advances in gut health. Dope entrepreneurs is led by Onikepe Adegbola, MD PhD DipIBLM, physician, scientist, and gut health entrepreneur.

Categories

  • Research
  • News
  • Articles
  • Reviews
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms And Conditions


© 2022 Dope Entrepreneurs

No Result
View All Result
  • Research
  • News
  • Articles
  • Reviews

© 2022 Dope Entrepreneurs

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist